Valuation
- Market cap
- 7,502,000
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 700
- Avg volume
- 1,439
- Day's range
- $1.10 – $1.11
- Shares out
- 6,820,000
- Stochastic %K
- 83%
- Beta
- 1.31
- Analysts
- —
- Price target
- —
Company profile
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug con...
Show more
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 561 907 8990
- Website
- https://curativebiotech.com
- Address
- 3801 PGA Blvd, Suite 600, Palm Beach Gardens, United States
Latest news
No headlines yet.
